FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:349-350 February 4, 1993 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Research on the pathogenesis and treatment of peptic ulcer disease is yielding surprising discoveries that will change the medical approach to ulcer therapy. Among the most surprising is the fact that peptic ulcer disease is often a curable infectious disorder.

We now recognize three major causes of peptic ulcer disease: Helicobacter pylori infection, the use of nonsteroidal antiinflammatory drugs (NSAIDs), and pathologic hypersecretory states such as the Zollinger-Ellison syndrome¹. Although the mechanisms of ulcer formation by H. pylori remain obscure, the results of the trial reported by Hentschel et al. in this issue of the Journal² and also those . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Candelli, M., Rigante, D., Marietti, G., Nista, E. C., Crea, F., Bartolozzi, F., Schiavino, A., Pignataro, G., Silveri, N. G., Gasbarrini, G., Gasbarrini, A. (2003). Helicobacter pylori, Gastrointestinal Symptoms, and Metabolic Control in Young Type 1 Diabetes Mellitus Patients. Pediatrics 111: 800-803 [Abstract] [Full Text]  
• Kanamaru, T., Nakano, Y., Toyoda, Y., Miyagawa, K.-I., Tada, M., Kaisho, T., Nakao, M. (2001). In Vitro and In Vivo Antibacterial Activities of TAK-083, an Agent for Treatment of Helicobacter pylori Infection. Antimicrob. Agents Chemother. 45: 2455-2459 [Abstract] [Full Text]  
• Hood, H. M., Wark, C., Burgess, P. A., Nicewander, D., Scott, M. W. (1999). Screening for Helicobacter pylori and Nonsteroidal Anti-inflammatory Drug Use in Medicare Patients Hospitalized With Peptic Ulcer Disease. Arch Intern Med 159: 149-154 [Abstract] [Full Text]  
• Donovan, A. J., Berne, T. V., Donovan, J. A. (1998). Perforated Duodenal Ulcer: An Alternative Therapeutic Plan. Arch Surg 133: 1166-1171 [Abstract] [Full Text]  
• TSANG, K. W., LAM, S.-K., LAM, W.-K., KARLBERG, J., WONG, B. C., HU, W. H., YEW, W.-W., IP, M. S. (1998). High Seroprevalence of Helicobacter pylori in Active Bronchiectasis. Am. J. Respir. Crit. Care Med. 158: 1047-1051 [Abstract] [Full Text]  
• Fennerty, M. B., Kovacs, T. O. G., Krause, R., Haber, M., Weissfeld, A., Siepman, N., Rose, P. (1998). A Comparison of 10 and 14 Days of Lansoprazole Triple Therapy for Eradication of Helicobacter pylori. Arch Intern Med 158: 1651-1656 [Abstract] [Full Text]  
• Moshkowitz, M., Reif, S., Brill, S., Ringel, Y., Arber, N., Halpern, Z., Bujanover, Y. (1998). One-Week Triple Therapy With Omeprazole, Clarithromycin, and Nitroimidazole for Helicobacter pylori Infection in Children and Adolescents. Pediatrics 102: e14-14 [Abstract] [Full Text]  
• Walsh, J. H., Peterson, W. L. (1995). The Treatment of Helicobacter pylori Infection in the Management of Peptic Ulcer Disease. NEJM 333: 984-991 [Full Text]  
• Glickman, R. (1995). A 35-Year-Old Man With Epigastric Pain. JAMA 274: 495-500 [Abstract]  
• Andersen, M, Schou, J S (1994). Are H2 receptor antagonists safe over the counter drugs?. BMJ 309: 493-494 [Full Text]  
• Ransohoff, D. F. (1993). Gastroenterology. JAMA 270: 206-209 [Abstract]